Citation

Stoffers-Winterling J, Storebø OJ, Lieb K. Curr. Psychiatry Rep. 2020; 22(8): e37.

Copyright

(Copyright © 2020, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s11920-020-01164-1

PMID

32504127

PMCID

PMC7275094

Abstract

PURPOSE OF THE REVIEW: We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.
RECENT FINDINGS: We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others. The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.

Language: en

Keywords

Humans; Suicide; Review; Randomized Controlled Trials as Topic; Self-Injurious Behavior; Antidepressants; Borderline personality disorder; Antipsychotics; Lamotrigine; Anticonvulsants; Borderline Personality Disorder; Drug treatment; Selective Serotonin Reuptake Inhibitors